HC Wainwright Has Positive Outlook of Ocugen FY2025 Earnings

Key Points

• HC Wainwright has increased its FY2025 earnings per share (EPS) estimate for Ocugen to ($0.20), up from ($0.21), while maintaining a "Buy" rating and a $7.00 target price.
• For the most recent quarter, Ocugen reported earnings of ($0.05) per share, exceeding analyst expectations of ($0.06), with revenue of $1.37 million against analyst estimates of $0.35 million.
• Several institutional investors have increased their stakes in Ocugen, with Vanguard Personalized Indexing Management boosting its position by 48.8% during the second quarter.

Ocugen, Inc. (NASDAQ:OCGN - Free Report) - Analysts at HC Wainwright boosted their FY2025 EPS estimates for Ocugen in a note issued to investors on Monday, August 4th. HC Wainwright analyst S. Ramakanth now anticipates that the company will earn ($0.20) per share for the year, up from their prior estimate of ($0.21). HC Wainwright currently has a "Buy" rating and a $7.00 target price on the stock. The consensus estimate for Ocugen's current full-year earnings is ($0.20) per share. HC Wainwright also issued estimates for Ocugen's FY2027 earnings at ($0.08) EPS, FY2028 earnings at $0.24 EPS and FY2029 earnings at $1.13 EPS.

Ocugen (NASDAQ:OCGN - Get Free Report) last released its quarterly earnings data on Friday, August 1st. The company reported ($0.05) earnings per share for the quarter, topping the consensus estimate of ($0.06) by $0.01. Ocugen had a negative return on equity of 255.25% and a negative net margin of 1,197.71%. The business had revenue of $1.37 million during the quarter, compared to analysts' expectations of $0.35 million.

Separately, Chardan Capital restated a "buy" rating and issued a $7.00 price objective on shares of Ocugen in a report on Monday.

Ocugen Stock Performance

Shares of OCGN stock opened at $0.96 on Thursday. The firm has a market capitalization of $280.12 million, a price-to-earnings ratio of -4.79 and a beta of 3.84. The stock has a fifty day moving average of $1.03 and a 200 day moving average of $0.81. Ocugen has a 52 week low of $0.52 and a 52 week high of $1.40. The company has a quick ratio of 2.60, a current ratio of 1.83 and a debt-to-equity ratio of 9.18.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the company. Vanguard Personalized Indexing Management LLC boosted its position in shares of Ocugen by 48.8% during the second quarter. Vanguard Personalized Indexing Management LLC now owns 29,871 shares of the company's stock valued at $29,000 after purchasing an additional 9,791 shares in the last quarter. BNP Paribas Financial Markets bought a new stake in shares of Ocugen during the 4th quarter valued at $30,000. Ameriprise Financial Inc. purchased a new stake in shares of Ocugen in the 4th quarter worth about $30,000. Baader Bank Aktiengesellschaft grew its position in shares of Ocugen by 108.8% in the 2nd quarter. Baader Bank Aktiengesellschaft now owns 38,142 shares of the company's stock worth $37,000 after buying an additional 19,876 shares during the period. Finally, Tower Research Capital LLC TRC increased its stake in shares of Ocugen by 309.6% in the 4th quarter. Tower Research Capital LLC TRC now owns 39,848 shares of the company's stock worth $32,000 after acquiring an additional 30,120 shares in the last quarter. Institutional investors own 10.27% of the company's stock.

Ocugen Company Profile

Ocugen, Inc, a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.